You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

CLARITIN-D Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Claritin-d patents expire, and when can generic versions of Claritin-d launch?

Claritin-d is a drug marketed by Bayer Healthcare Llc and is included in two NDAs.

The generic ingredient in CLARITIN-D is loratadine; pseudoephedrine sulfate. There are thirty-nine drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the loratadine; pseudoephedrine sulfate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CLARITIN-D?
  • What are the global sales for CLARITIN-D?
  • What is Average Wholesale Price for CLARITIN-D?
Summary for CLARITIN-D
US Patents:0
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Clinical Trials: 27
Drug Sales Revenues: Drug sales revenues for CLARITIN-D
What excipients (inactive ingredients) are in CLARITIN-D?CLARITIN-D excipients list
DailyMed Link:CLARITIN-D at DailyMed
Drug patent expirations by year for CLARITIN-D
Drug Sales Revenue Trends for CLARITIN-D

See drug sales revenues for CLARITIN-D

Recent Clinical Trials for CLARITIN-D

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Andover Research Eye InstitutePhase 4
National Cancer Institute (NCI)Early Phase 1
Rutgers, The State University of New JerseyEarly Phase 1

See all CLARITIN-D clinical trials

Pharmacology for CLARITIN-D

US Patents and Regulatory Information for CLARITIN-D

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc CLARITIN-D loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 019670-002 Nov 27, 2002 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bayer Healthcare Llc CLARITIN-D 24 HOUR loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 020470-002 Nov 27, 2002 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CLARITIN-D

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Healthcare Llc CLARITIN-D loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 019670-002 Nov 27, 2002 ⤷  Sign Up ⤷  Sign Up
Bayer Healthcare Llc CLARITIN-D loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 019670-002 Nov 27, 2002 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CLARITIN-D

See the table below for patents covering CLARITIN-D around the world.

Country Patent Number Title Estimated Expiration
Japan H03502696 ⤷  Sign Up
Portugal 73200 PROCESS FOR PREPARING NOVEL ANTIHISTAMINES ⤷  Sign Up
Denmark 469485 ⤷  Sign Up
Spain 8300779 ⤷  Sign Up
Japan H0631220 ⤷  Sign Up
Japan 2511412 ⤷  Sign Up
Japan H0572910 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CLARITIN-D

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1110543 08C0004 France ⤷  Sign Up PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
0152897 SPC/GB01/012 United Kingdom ⤷  Sign Up PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
0152897 2001C/013 Belgium ⤷  Sign Up PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
0152897 C00152897/01 Switzerland ⤷  Sign Up FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.